Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Roche reports positive studies of MabThera given by subcutaneous injection
The mystery of missing heritability: Genetic interactions create phantom heritability.
Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS.
New data analyses show significant clinical and MRI improvements with PLEGRIDY™ (peginterferon beta-1a)
Assessment of statistical significance and clinical relevance.
Disrupted balance of T cells under natalizumab treatment in multiple sclerosis.
Assessment of Disease Activity in Multiple Sclerosis Phenotypes with Combined Gadolinium- and Superparamagnetic Iron Oxide-enhanced MR Imaging.
Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench.
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis.
PI(3,5)P2 biosynthesis regulates oligodendrocyte differentiation by intrinsic and extrinsic mechanisms.
Bruxism and temporal bone hypermobility in patients with multiple sclerosis.
Remyelination therapy goes to trial for multiple sclerosis
Generation and Characterization of Fully Human Monoclonal Antibodies Against Human Orai1 for Autoimmune Disease.
Effects of murine and human bone marrow-derived mesenchymal stem cells on cuprizone induced demyelination.
IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis.
Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study.
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
B-07The Cognitive Health Questionnaire: Initial Psychometric Data in a Multisite Multiple Sclerosis Sample.
Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients.
No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
Disease-modifying treatments for progressive multiple sclerosis.
Long-Term Cost-Effectiveness Model of Interferon Beta-1b in the Early Treatment of Multiple Sclerosis in the United States.

Pages